Escitalopram

Bibliography

• KESSLER RC, MCGONAGLE KA, ZHAO S et al.: Lifetime and 12 month prevalence of DSM III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch. Gen. Psychiatry(1994) 51:8–19.
   PubMed Web of Science ®Google Scholar
• LEPINE JP, GASTPAR M, MENDLEWICZ J, TYLEE A: Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). Int. Clin. Psychopharmacol (1997) 12:19–29.
   PubMed Web of Science ®Google Scholar
• MURRAY CJ, LOPEZ AD: Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet (1997) 349:1436–1442.
   PubMed Web of Science ®Google Scholar
• HIRSCHFELD RM: Antidepressants in long-term therapy: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors. Acta Psychiatr. Scand. Sapp]. (2000) 403:35–38.
   Web of Science ®Google Scholar
• ZIMMERMAN M, MCDERMUT W, MATTIA JI: Frequency of anxiety disorders in outpatients with major depressive disorder. Am. j Psychiatry (2000) 157:1337–1340.
   PubMed Web of Science ®Google Scholar
• LESPERANCE F, FRASURE-SMITH N, TALAJIC M, BOURASSA MG: Five-year risk of cardiac mortality in relation to initial severity and one-year changes in depression symptoms after myocardial infarction. Circulation (2002) 105:1049–1053.
   PubMed Web of Science ®Google Scholar
• OKUN MS, WATTS RL: Depression associated with Parkinson's disease: clinical features and treatment. Neurology (2002) 58(4, Suppl. 1):S63–S70.
   Google Scholar
• STARKSTEIN SE, PREZIOSI TJ, BERTIER ML, BOLDUC PL, MAYBERG HS, ROBINSON RG: Depression and cognitive impairment in Parkinson's disease. Bran] (1989) 112:1141–1153.
   PubMed Web of Science ®Google Scholar
• ELLIOTT AJ, RUSSO J, ROY-BYRNE PP: The effect of changes in depression on health related quality of life (HRQoL) in HIV infection. Gen. Hosp. Psychiatry (2002) 24:43–47.
   PubMed Web of Science ®Google Scholar
• LESERMAN J, JACKSON ED, PETITTO JM et al.: Progression to AIDS: the effects of stress, depressive symptoms, and social support. Psychosom. Med. (1999) 61:397–406.
   PubMed Web of Science ®Google Scholar
• MENDLEWICZ J, LECRUBIER Y: Antidepressant selection: proceedings from a TCA/SSRI Consensus Conference. Acta Psych/at. Scand. Sapp]. (2000) 403:5–8.
   Web of Science ®Google Scholar
• KELLER MB. Citalopram therapy for depression: a review of 10 years of European experience and data from US clinical trials. .1 Clin. Psychiatry (2000) 61:896–908.
   PubMed Web of Science ®Google Scholar
• HYTTEL J, BOGESO KP, PERREGAARD J, SANCHEZ C: The pharmacological effect of citalopram resides in the (5) - (+) enantiomer.f Neural. Transm. (1992) 88:157–160.
   PubMed Web of Science ®Google Scholar
• •Demonstrates that the therapeutic activity of citalopram is attributable to enantiomer.
   Google Scholar
• SANCHEZ C, BRENNUM LT: Escitalopram is a highly selective and potent serotonin reuptake inhibitor. hi vitro studies. Scandinavian College of Neuro-Psychopharmacology 1st Annual Meeting. Juan Les Pins, France (18–21 April 2001).
   Google Scholar
• SANCHEZ C, HOGG S: The antidepressant effect of citalopram resides in the S-enantiomer (Lu 26–054). 55th Annual Scientific Conference of the Socieg, of Biological Psychiatry Chicago, IL, USA (11–13 May 2000).
   Google Scholar
• BERGQVIST PBF, BRENNUM LT, SANCHEZ C: Escitalopram mediates citalopram inhibition of DRN-5HT neural activity. 154th Annual Meeting of the American Psychiatric Association, New Orleans, LA, USA (5–10 May 2001).
   Google Scholar
• MORK A, KREILGAARD M, SANCHEZ C, BRENNUM LT, WIBORG 0: Escitalopram: a comparative study of in vitro and in vivo 5-HT uptake inhibitory activity. 23rd Congress of the Collegium Internationale Neuro-Psychopharmacolgicum, Montreal, Canada (23–27 June 2002).
   Google Scholar
• ••Shows activity of R-citalopram to interferewith therapeutic effects of escitalopram.
   Google Scholar
• OWENS MJ, KNIGHT DL, NEMEROFF CB: Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol. Psychiatry(2001) 50:345–350.
   PubMed Web of Science ®Google Scholar
• ••Demonstrates that escitalopram is themost selective SSRI studied to date.
   Google Scholar
• MITCHELL PJ, HOGG S: Escitalopram: behavioral model predicts antidepressant activity. 56th Annual Scientific Conference of Biological Psychiatry New Orleans, LA, USA (3–5 May 2001).
   Google Scholar
• PAPP M, SANCHEZ C: Escitalopram: potent and rapid in chronic mild stress model of depression. 154th Annual Meeting of the American Psychiatric Association, New Orleans, LA, USA (5–10 May 2001).
   Google Scholar
• MONTGOMERY SA, LOFT H, SANCHEZ C, REINES EH, PAPP M: Escitalopram (S-enantiomer of citalopram): clinical efficacy and onset of action predicted from a rat model. Pharmacol Toxicol (2001) 88:282–286.
   PubMedGoogle Scholar
• ••Suggests earlier onset of effect ofescitalopram compared with citalopram in rat model and clinical trial.
   Google Scholar
• SANCHEZ C, PAPP M: The selective sigma2 ligand Lu-28-179 has an antidepressant-like profile in the rat chronic mild stress model of depression. Behav. Pharmacol (2000) 11:117–124.
   PubMed Web of Science ®Google Scholar
• SANCHEZ C: Escitalopram has potent amdolytic effects in rodent anxiety models. 7th World Congress of Biological Psychiatry Berlin, Germany (1–6 July 2001).
   Google Scholar
• GUTIERREZ M, MENGEL H: Pharmacokinetics of escitalopram. 42nd Annual New Clinical Drug Evaluation Unit (NCDEU) Meeting, Boca Raton, FL, USA (10–13 June 2002).
   Google Scholar
• DREWES P, TJIJSSEN I, MENGEL H, LARSEN F: A single-dose cross-over pharmacolkinetic study comparing racemic citalopram (40 mg) with the Senantiomer of citalopram (escitalopram, 20 mg) in healthy male subjects. 41st Annual Meeting of the New Clinical Drug Evaluation Unit, Phoenix, AZ, USA (28–31 May 2001).
   Google Scholar
• ROCHAT B, AMEY M, BAUMANN P: Analysis of enantiomers of citalopram and its demethylated metabolites in plasma of depressive patients using chiral reverse-phase liquid chromatography. Thec Drug Monit. (1995) 3:273–279.
   Web of Science ®Google Scholar
• VON MOLTKE LL, GREENBLATT DJ, GIANCARLO GM, GRANDA BW, HARMATZ JS, SHADER RI: Escitalopram (S-citalopram) and its metabolites M vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metal,. Dispos. (2001) 8:1102–1109.
   Google Scholar
• ••Shows escitalopram to have weak ornegligible effects on CYP450 enzymes in vitro.
   Google Scholar
• GUTIERREZ M, ROSENBERG J, ABRAMOWITZ W: Lack of a pharamcokinetic interaction between escitalopram and the CYP3A4 inhibitor ritonovir. 41st Annual Meeting of the New Clinical Drug Evaluation Unit (NCDEU), Phoenix, AZ, USA (23–31 May 2001).
   Google Scholar
• BEERS MH, BERKOW R (Eds.): The Merck Manual (17th edition). Merck Research Laboratories, Whitehouse Station, NJ, USA (1999):2584.
   Google Scholar
• WADE A, LEMMING OM, HEDEGAARD KB: Escitalopram 10 mg/ day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int. Clin. Psychopharmacol (2002) 17:95–102.
   PubMed Web of Science ®Google Scholar
• ••Demonstrates that escitalopram 10 mg/day is a safe, effective, and well-tolerated dose for treatment of depression.
   Google Scholar
• BURKE WJ, GERGEL I, BOSE A: Fixed dose trial of the single isomer SSRI escitalopram in depressed outpatients. Clin. Psychiatry (2002) 63:331–336.
   PubMed Web of Science ®Google Scholar
• ••Demonstrates that escitalopram 10 mg/day is as effective as citalopram 40 mg/day.
   Google Scholar
• TRIVEDI M, LEPOLA U: Flexible-dose experience with escitalopram in the treatment of major depressive disorder. Annual Meeting of the American College of Neuropsychopharmacology Waikoloa Village, HI, USA (9–13 December 2001).
   Google Scholar
• GORMAN JM, KOROTZER A, SU G: Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectrum (2002) 7\(Suppl. 1):40–44.
   Google Scholar
• ••Suggests that escitalopram has superiorclinical efficacy compared with citalprarn.
   Google Scholar
• FEIGHNER JP, OVERO K: Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression.j Clin. Psychiatry (1999) 60:824–830.
   PubMed Web of Science ®Google Scholar
• MENDELS J, KIEV A, FABRE LF: Double-blind comparison of citalopram and placebo in depressed outpatients with melancholia. Depress. Anxiety (1999) 9:54–60.
   PubMedGoogle Scholar
• RAPAPORT M, BOSE A, ZHENG H, KOROTZER A: Escitalopram prevents relapse of depressive episodes. Annual Meeting of The American College of Neuropsychopharmacology Waikoloa Village, HI, USA (9–13 December 2001).
   Google Scholar
• •Demonstrates escitalopram is effective in prevention of relapse of depression.
   Google Scholar
• DAVIDSON J, BOSE A, SU G: Escitalopram in the treatment of generalized anxiety disorder. 42nd Annual New Clinical Drug Evaluation Unit (NCDEL) Meeting. Boca Raton, FL, USA (10–13 June 2002).
   Google Scholar
• •Suggests escitalopram is safe, effective, and well-tolerated in the treatment of GAD.
   Google Scholar
• STAHL SM, GERGEL I, LID, KOROTZER A: Escitalopram in the treatment of panic disorder. 155th Annual Meeting of the American Psychiatric Association. Philadelphia, PA,USA (18–23 May 2002).
   Google Scholar
• •Suggests escitalopram is safe, effective, and well-tolerated in the treatment of panic disorder.
   Google Scholar
• KASPER S, LOFT H, SMITH JR: Escitalopram is efficacious and well tolerated in the treatment of social anxiety disorder. 155th Annual Meeting of the American Psychiatric Association. Philadelphia, PA, USA (18–23 May 2002).
   Google Scholar
• •Suggests escitalopram is safe, effective, and well-tolerated in the treatment of social anxiety disorder.
   Google Scholar
• GERGEL I, HAKKARAINEN H, ZORNBERG G, KOROTZER A: Escitalopram is a well tolerated SSRI. 155th Annual Meeting of the American Psychiatric Association. Philadelphia, PA, USA (18–23 May 2002).
   Google Scholar
• ROSENBAUM JF, HAKKARAINEN H, SU G: Comparison of safety in placebo-controlled trials of escitalopram and citalopram. 42nd Annual New Clinical Drug Evaluation Unit (NCDEL) Meeting Boca Raton, FL, USA (10–13 June 2002).
   Google Scholar
• STAHL SM: Using secondary binding properties to select a not so selective serotonin reuptake inhibitor. j. Clin. Psychiatry (1998) 59:642–643.
   PubMed Web of Science ®Google Scholar
• STAHL SM: Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline. Biol. Psychiatry (2000) 48:894–901.
   PubMed Web of Science ®Google Scholar
• BROWN WA, HARRISON W: Are patients who are intolerant to one serotonin selective reuptake inhibitor intolerant to another? Clin. Psychiatry (1995) 56:30–4.
   Google Scholar
• THASE ME, FEIGHNER JP, LYDIARD RB: Citalopram treatment of fluoxetine nonresponders.j Clin. Psychiatry (2001) 62:683–687.
   PubMed Web of Science ®Google Scholar